Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.70B | 7.68B | 7.39B | 6.94B | 6.83B | 7.02B |
Gross Profit | 5.47B | 5.49B | 5.31B | 4.92B | 4.87B | 4.90B |
EBITDA | 2.30B | 2.25B | 2.21B | 2.21B | 2.16B | 969.70M |
Net Income | 913.40M | 903.80M | 1.02B | 231.40M | 401.60M | -137.40M |
Balance Sheet | ||||||
Total Assets | 22.18B | 21.37B | 21.50B | 21.07B | 23.46B | 24.42B |
Cash, Cash Equivalents and Short-Term Investments | 1.38B | 525.50M | 415.80M | 375.70M | 378.10M | 802.10M |
Total Debt | 7.18B | 6.20B | 6.00B | 5.70B | 7.08B | 8.13B |
Total Liabilities | 9.78B | 8.89B | 9.01B | 9.04B | 10.79B | 12.22B |
Stockholders Equity | 12.40B | 12.47B | 12.48B | 12.02B | 12.66B | 12.20B |
Cash Flow | ||||||
Free Cash Flow | 1.35B | 1.14B | 1.20B | 1.10B | 1.35B | 1.09B |
Operating Cash Flow | 1.65B | 1.50B | 1.58B | 1.28B | 1.50B | 1.20B |
Investing Cash Flow | -799.10M | -888.10M | -778.90M | -529.20M | -503.60M | -613.80M |
Financing Cash Flow | 141.00M | -484.50M | -763.50M | -843.80M | -1.31B | -421.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $154.34B | 76.44 | 9.65% | ― | 19.35% | 14.31% | |
74 Outperform | $154.34B | 76.44 | 9.65% | ― | 19.35% | 14.31% | |
73 Outperform | $151.06B | 53.34 | 14.26% | 0.85% | 10.76% | -15.22% | |
73 Outperform | $151.06B | 53.34 | 14.26% | 0.85% | 10.76% | -15.22% | |
71 Outperform | $13.22B | 31.71 | 7.86% | 3.05% | 4.58% | 55.99% | |
71 Outperform | $13.22B | 31.71 | 7.86% | 3.05% | 4.58% | 55.99% | |
68 Neutral | $18.53B | 20.76 | 7.31% | 1.02% | 3.30% | -2.39% | |
58 Neutral | $8.01B | 44.26 | 4.63% | ― | 32.26% | 112.87% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
49 Neutral | $9.72M | ― | -151.23% | ― | 3.30% | 31.84% | |
49 Neutral | $9.72M | ― | -151.23% | ― | 3.30% | 31.84% |
On June 27, 2025, Zimmer Biomet Holdings, Inc. entered into a new five-year revolving credit agreement and a 364-day revolving credit agreement, replacing their previous credit agreements. The five-year agreement provides a $1.5 billion unsecured revolving facility, with the possibility of increasing by up to $500 million, and will be used for general corporate purposes. This move is expected to enhance the company’s financial flexibility and support its strategic initiatives, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (ZBH) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.
Zimmer Biomet Holdings, Inc. held its annual meeting on May 29, 2025, where shareholders approved significant amendments to the 2009 Stock Incentive Plan (SIP) and the company’s Restated Certificate of Incorporation. The amendments to the SIP include an increase in available shares, extension of the plan’s term, and new provisions for independent contractors, among others. The amendment to the Certificate of Incorporation limits the personal liability of certain officers for monetary damages under specific circumstances. These changes are expected to enhance corporate governance and align with best practices, potentially impacting the company’s operational and strategic positioning.
The most recent analyst rating on (ZBH) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.
On May 27, 2025, Zimmer Biomet Holdings announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas, effective July 1, 2025. Thornal, who previously served as CEO of Nevro Corp., brings extensive experience in the medical technology, orthopedics, and diagnostics industries. His leadership is expected to enhance Zimmer Biomet’s commercial execution and stakeholder value, as the company aims to address unmet needs in musculoskeletal health and expand its product pipeline.
The most recent analyst rating on (ZBH) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.